Literature DB >> 11082108

Pharmacology and autoradiography of human DP prostanoid receptors using [(3)H]-BWA868C, a DP receptor-selective antagonist radioligand.

N A Sharif1, G W Williams, T L Davis.   

Abstract

1. A potent and highly selective DP prostanoid receptor antagonist radioligand, [(3)H]-cyclohexyl-N-BWA868C (3-benzyl-5-(6-carboxyhexyl)-1-(2-cyclohexyl-2-hydroxyethyl-amino) hydantoin, ([(3)H]-BWA868C)), has been generated for receptor binding and autoradiographic studies. 2. Specific [(3)H]-BWA868C binding to human platelet membranes achieved equilibrium within 60 min at 23 degrees C and constituted up to 95% of the total binding. The association (K(+1)) and dissociation (K(-1)) rate constants of binding were 0.758+/-0.064 min(-1), mmol and 0.0042+/-0.0002 min(-1), respectively, yielding dissociation constants (K(D)s) of 5.66+/-0. 44 nM (n=4). 3. Specific [(3)H]-BWA868C bound to DP receptors with a high affinity (K(D)=1.45+/-0.01 nM, n=3) and to a finite, saturable number of binding sites (B(max)=21.1+/-0.6 nmol g(-1) wet weight). 4. DP receptor class prostanoids (e.g. ZK118182, BW245C, BWA868C, PGD(2)) exhibited high (nanomolar) affinities for [(3)H]-BWA868C binding, while prostanoids selective for EP, FP, IP and TP receptors showed a low (micromolar) affinity. 5. Specific DP receptor binding sites were autoradiographically localized on the ciliary epithelium/process, longitudinal and circular ciliary muscles, retinal choroid and iris in human eye sections using [(3)H]-BWA868C. While [(3)H]-PGD(2) yielded similar quantitative distribution of DP receptors as [(3)H]-BWA868C, the level of non-specific binding observed with [(3)H]-PGD(2) was significantly greater than that observed with [(3)H]-BWA868C. 6. It is concluded that [(3)H]-BWA868C is a high-affinity and very specific DP receptor radioligand capable of selectively labelling the DP receptor. [(3)H]-BWA868C may prove useful for future homogenate-based and autoradiographic studies on the DP receptor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11082108      PMCID: PMC1572442          DOI: 10.1038/sj.bjp.0703686

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  38 in total

Review 1.  Biological aspects of prostaglandins.

Authors:  N H Andersen; P W Ramwell
Journal:  Arch Intern Med       Date:  1974-01

Review 2.  The biology and pharmacology of PGD2.

Authors:  H Giles; P Leff
Journal:  Prostaglandins       Date:  1988-02

3.  Ligand: a versatile computerized approach for characterization of ligand-binding systems.

Authors:  P J Munson; D Rodbard
Journal:  Anal Biochem       Date:  1980-09-01       Impact factor: 3.365

4.  A practical computer-based approach to the analysis of radioligand binding experiments.

Authors:  G A McPherson
Journal:  Comput Programs Biomed       Date:  1983 Aug-Oct

5.  Stable 9 beta- or 11 alpha-halogen-15-cyclohexyl-prostaglandins with high affinity to the PGD2-receptor.

Authors:  K H Thierauch; C S Stürzebecher; E Schillinger; H Rehwinkel; B Radüchel; W Skuballa; H Vorbrüggen
Journal:  Prostaglandins       Date:  1988-06

6.  Characterization of the platelet prostaglandin D2 receptor. Loss of prostaglandin D2 receptors in platelets of patients with myeloproliferative disorders.

Authors:  B Cooper; D Ahern
Journal:  J Clin Invest       Date:  1979-08       Impact factor: 14.808

7.  Quantitative autoradiographic visualization and pharmacology of FP-prostaglandin receptors in human eyes using the novel phosphor-imaging technology.

Authors:  T L Davis; N A Sharif
Journal:  J Ocul Pharmacol Ther       Date:  1999-08       Impact factor: 2.671

8.  Specificity of prostaglandin D2 binding to synaptic membrane fraction of rat brain.

Authors:  H Tokumoto; Y Watanabe; A Yamashita; Y Arai; O Hayaishi
Journal:  Brain Res       Date:  1986-01-01       Impact factor: 3.252

9.  Specific binding of prostaglandin D2 to rat brain synaptic membrane. Occurrence, properties, and distribution.

Authors:  T Shimizu; A Yamashita; O Hayaishi
Journal:  J Biol Chem       Date:  1982-11-25       Impact factor: 5.157

10.  Pharmacological and cardiovascular properties of a hydantoin derivative, BW 245 C, with high affinity and selectivity for PGD2 receptors.

Authors:  M H Town; J Casals-Stenzel; E Schillinger
Journal:  Prostaglandins       Date:  1983-01
View more
  9 in total

Review 1.  Effects of prostaglandin analogues on aqueous humor outflow pathways.

Authors:  Nelson S Winkler; Michael P Fautsch
Journal:  J Ocul Pharmacol Ther       Date:  2013-12-20       Impact factor: 2.671

Review 2.  A Review of Prostanoid Receptors: Expression, Characterization, Regulation, and Mechanism of Action.

Authors:  Roger G Biringer
Journal:  J Cell Commun Signal       Date:  2020-09-24       Impact factor: 5.782

3.  Discovery to Launch of Anti-allergy (Emadine; Patanol/Pataday/Pazeo) and Anti-glaucoma (Travatan; Simbrinza) Ocular Drugs, and Generation of Novel Pharmacological Tools Such as AL-8810.

Authors:  Najam A Sharif
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-05

Review 4.  Prostaglandin FP receptor antagonists: discovery, pharmacological characterization and therapeutic utility.

Authors:  Najam A Sharif; Peter G Klimko
Journal:  Br J Pharmacol       Date:  2018-06-07       Impact factor: 8.739

5.  Excitotoxicity-induced prostaglandin D2 production induces sustained microglial activation and delayed neuronal death.

Authors:  Kensuke Iwasa; Shinji Yamamoto; Sosuke Yagishita; Kei Maruyama; Keisuke Yoshikawa
Journal:  J Lipid Res       Date:  2017-02-07       Impact factor: 5.922

Review 6.  Neuroaxonal and cellular damage/protection by prostanoid receptor ligands, fatty acid derivatives and associated enzyme inhibitors.

Authors:  Najam A Sharif
Journal:  Neural Regen Res       Date:  2023-01       Impact factor: 6.058

7.  PGD(2) DP1 receptor protects brain from ischemia-reperfusion injury.

Authors:  Sofiyan Saleem; Hean Zhuang; Artur J de Brum-Fernandes; Takayuki Maruyama; Shuh Narumiya; Sylvain Doré
Journal:  Eur J Neurosci       Date:  2007-06-16       Impact factor: 3.386

Review 8.  Retinopathy of prematurity: inflammation, choroidal degeneration, and novel promising therapeutic strategies.

Authors:  José Carlos Rivera; Mari Holm; Dordi Austeng; Tora Sund Morken; Tianwei Ellen Zhou; Alexandra Beaudry-Richard; Estefania Marin Sierra; Olaf Dammann; Sylvain Chemtob
Journal:  J Neuroinflammation       Date:  2017-08-22       Impact factor: 8.322

Review 9.  A review of non-prostanoid, eicosanoid receptors: expression, characterization, regulation, and mechanism of action.

Authors:  Roger G Biringer
Journal:  J Cell Commun Signal       Date:  2021-06-26       Impact factor: 5.782

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.